Charles River to buy WuXi Pharma for $1.6 billion
2010-04-26 12:56:00.0
Track China's Leaders
MUNICH - Siemens Chief Executive Peter Loescher is to leave the company, four years before the end of his contract, after the German engineering group this week issued its second profit warning this year.
NEW YORK - Small business owners plan for growth this year but are closely tracking recent interest rate rises and any impact they might have on their business and customers, according to a spot survey of firms in the New York region.
Mon, Apr 26 2010
Sun, Apr 25 2010
Fri, Apr 16 2010
Fri, Apr 16 2010
Fri, Apr 9 2010
Mon  EDT
) said on Monday it had agreed to buy China's WuXi PharmaTech (
The deal will create the first global contract research organization offering fully integrated early-stage drug development services to clients worldwide, Charles River said in a statement.
As per the deal, Charles River will offer $21.25 per WuXi American Depositary Share and each WuXi ADS will be exchanged for $11.25 in cash and $10 of Charles River common stock determined by an exchange ratio, the company said.
Charles River has focused on developing drugs before they go to clinical trials. WuXi has been active in drug chemistry, such as making molecules to synthesize a drug.
(Reporting by Sakthi Prasad in Bangalore; Editing by Muralikumar Anantharaman)
